Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
This article was originally published in The Pink Sheet Daily
The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.
You may also be interested in...
Mortality for this deadly disease has been pushed back due to therapeutic innovations. But to make further strides, new mechanisms of action and combination approaches will need to come further into play. These advances and the eventual genericization of Velcade are likely to make the regulatory and payer environment increasingly complicated.
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.